Additive Effect of Oral Tetradecanoic Acid to Tamsulosin and Finasteride in a Benign Prostatic Hyperplasia Rat Model

Anup Patil; Dr. R.C. Doijad; Dr. P.V. Salve; A.A. Koparde

Authors

Anup Patil
Dr. R.C. Doijad
Dr. P.V. Salve
A.A. Koparde

Keywords:

5alpha-reductase inhibitor, tetradecanoic acid, tamsulosin, finasteride

Abstract

We investigated the benefit of the tetradecanoic acid combined with tamsulosin and finasteride, in a benign prostatic hyperplasia (BPH) rat model. By bilateral orchiectomy under ketamine anesthesia Castration was performed. A rat model of BPH was established by daily intramuscular administration of testosterone propionate plus 17 alpha-estradiol for 8 weeks. For 4 weeks from week 6 to 9 post-surgery model rats were administered combinations of 20 mg/kg of tetradecanoic acid, 0.01 mg/kg tamsulosin and 1 mg/kg finasteride once daily by oral gavage. Body and genitourinary organ weights were recorded, serums were assayed for hormone concentrations, and tissues were subjected to histopathology Combined tetradecanoic acid, tamsulosin, and finasteride significantly decreased prostatic index, serum hormone levels, epithelial thickness, The 3-drug combination was more effective than any other combination or tetradecanoic acid alone. These results suggest that tetradecanoic acid addition to tamsulosin and finasteride may be beneficial for the treatment of BPH patients who do not respond to tamsulosin plus finasteride.

Downloads

How to Cite

Additive Effect of Oral Tetradecanoic Acid to Tamsulosin and Finasteride in a Benign Prostatic Hyperplasia Rat Model. (2020). Global Journal of Medical Research, 20(F5), 33-37. https://medicalresearchjournal.org/index.php/GJMR/article/view/2057

Download Citation

References

Bob Djavan (2003) Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life. 62(3), 6-14.

M Lee, I Shin, C Seo (2012) Effects of Melandrium firmum metha-nolic extract on testosterone-induced benign prostatic hyperplasia in Wistar rats. 14, 320-324.

P Sagnier, G Macfarlane, P Teillac, H Botto, F Richard, P Boyle (1995) Impact of symptoms of prostatism on level of bother and quality of life of men in the French community. 153, 669-673.

Y Lee, J Lee, J Park (2016) Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea. 57, 424-430.

Veeresh Babu, S Veeresh, B Patil, A Warke, Y (2010) Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats. 626, 262-265.

K Cho, C Park, C Kim, H Jeon, W Kim, S Lee, Y Kim, J Lee, Y Choi (2013) Effects of Korean ginseng berry extract (GB0710) on penile erection: evidence from in vitro and in vivo studies. 15(4), 503-507.

Culley Carson, Roger Rittmaster (2003) The role of dihydrotestosterone in benign prostatic hyperplasia. 61(4), 2-7.

S Fine, P Ginsberg (2008) Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential com-plications. 108, 333-337.

E Lee (2002) Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients. 30, 584-590.

J Mcconnell, C Roehrborn, O Bautista, G Andriole, Jr, C Dixon, J Kusek (2003) The long-term effect of doxazosin, finas-teride, and combination therapy on the clinical progression of benign prostatic hyperplasia. 349, 2387-2398.

Katsuyoshi Akiyama, Masachiyo Hora, Satoshi Tatemichi, Naoyuki Masuda, Syunji Nakamura, Ryoichi Yamagishi, Makio Kitazawa (1999) KMD-3213, a Uroselective and Long-Acting α1a-Adrenoceptor Antagonist, Tested in a Novel Rat Model. 291(1), 81-91.

Sung Lee, Jae Paick, Hyun Park, Ji Won, Yoji Morisaki, Sebastian Sorsaburu, Lars Viktrup (2014) The Efficacy and Safety of Tadalafil 5 mg Once Daily in Korean Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: An Integrated Analysis. 32(1), 28.

K Akiyama, M Hora, R Yamagishi, M Kitazawa (2002) Effects of KMD-3213, a uroselective alpha 1A-adrenoceptor antagonist, on the tilt-induced blood pressure response in normotensive rats. 90, 131-137.

Hyun Sung, Seol Choo, Deok Han, Mee Chae, Su Kang, Chul-Seung Park, Insuk So, Jong Park, Sung Lee (2015) Effect of the Novel BKCa Channel Opener LDD175 on the Modulation of Corporal Smooth Muscle Tone. 12(1), 29-38.

A Gormemis, T Ha, I Im (2005) Benzofuroindole analogues as potent BK (Ca) channel openers. 6, 1745-1748.

J Choi, J Choi, G Lee (2006) Acute toxicity of the BKCa channel opener LDD175. 14, 253-258.

K Suzuki, K Ito, T Suzuki, S Honma, H Yamanaka (1995) Synergistic effects of estrogen and androgen on the prostate: effects of estrogen on androgen-and estrogen-receptors, BrdU uptake, immunohistochemical study of AR, and responses to antiandrogens. 26, 151-163.

Hitoshi Kontani, Chisato Shiraoya (2002) Method for Simultaneous Recording of the Prostatic Contractile and Urethral Pressure Responses in Anesthetized Rats and the Effects of Tamsulosin. 90(3), 281-290.

Bo Choi, Kiran Soni, Li Zhang, Sung Lee, Insuk So, Hye Kim, Jong Park (2016) Effect of 4‐chloro‐7‐trifluoromethyl‐10H‐benzo[4,5]furo[3,2‐b]indole‐1‐carboxylic acid on the intraurethral pressure in a rat model of benign prostatic hyperplasia. 23(3), 259-265.

Alexander Opoku-Acheampong, Dave Unis, Jamie Henningson, Amanda Beck, Brian Lindshield (2013) Preventive and Therapeutic Efficacy of Finasteride and Dutasteride in TRAMP Mice. 8(10), e77738.

Luis Justulin Jr, Carolina Acquaro, Robson Carvalho, Maeli Silva, Sérgio Felisbino (2010) Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiology. 33(3), 489-499.

Marco Marcelli, Glenn Cunningham (1999) Hormonal Signaling in Prostatic Hyperplasia and Neoplasia*. 84(10), 3463-3468.

Gerald Andriole, Nicholas Bruchovsky, Leland Chung, Alvin Matsumoto, Roger Rittmaster, Claus Roehrborn, David Russell, Donald Tindall (2004) DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. 172(4 Part 1), 1399-1403.